Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy.
Martijn A van DamFloris A VuijkJudith A StibbeRuben D HouvastSaskia A C LuelmoStijn CrobachShirin Shahbazi FeshtaliLioe-Fee De Geus-OeiBert A BonsingCornelis F M SierPeter J K KuppenRutger-Jan SwijnenburgAlbert D WindhorstJacobus BurggraafAlexander L VahrmeijerJ Sven D MieogPublished in: Cancers (2021)
A literature search in the PubMed database and (inter)national trial registers was conducted, focusing on studies published over the last 15 years. Data and information of eligible articles regarding PET/CT as well as fluorescence imaging in PDAC were reviewed. Areas covered: This review covers the current strategies, obstacles, challenges, and developments in targeted tumor imaging, focusing on the feasibility and value of PET/CT and fluorescence imaging for integration in the work-up and treatment of PDAC. An overview is given of identified targets and their characteristics, as well as the available literature of conducted and ongoing clinical and preclinical trials evaluating PDAC-targeted nuclear and fluorescent tracers.
Keyphrases
- fluorescence imaging
- pet ct
- positron emission tomography
- photodynamic therapy
- cancer therapy
- systematic review
- computed tomography
- rectal cancer
- clinical trial
- pet imaging
- squamous cell carcinoma
- quality improvement
- electronic health record
- healthcare
- cell therapy
- mesenchymal stem cells
- living cells
- mass spectrometry
- adverse drug
- replacement therapy
- drug induced
- fluorescent probe